DOUBLE THE TIME (PFS)
Consistent results across all prespecified subgroups1


† Other than NSAI.
† Other than NSAI.
aBC, advanced breast cancer; AFI, AFINITOR; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; ECOG, Eastern Cooperative Oncology Group; EXE, exemestane; HR+, hormone receptor-positive; NSAI, nonsteroidal aromatase inhibitor; PFS, progression-free survival; PgR, progesterone receptor; PBO, placebo.
1. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870-884.